Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin-EIR in Moderate-to-Severe Papulopustular Rosacea
NCT05150587Phase 2Completed
- Sponsor
- Alfasigma
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in papulopustular rosacea, sponsored by Alfasigma. Started Oct 2021; status: completed.
02
Drugs
rifaximin
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT05150587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150587.